Company Filing History:
1 out of 2,943 
1 out of 4,455 
Years Active: 2020
Title: Zelanna Goldberg: Pioneering PD-L1 Antagonist Combination Treatments
Introduction
Zelanna Goldberg, an innovative inventor based in San Diego, California, is making significant contributions to the medical field with her groundbreaking work on cancer treatment. Her impressive portfolio includes a patent for a unique combination therapy aimed at enhancing cancer treatment effectiveness.
Latest Patents
Zelanna Goldberg holds a patent for her invention titled "PD-L1 Antagonist Combination Treatments". This patent outlines combination therapies that feature an antagonist of the Programmed Death Ligand 1 receptor (PD-L1) alongside another therapeutic agent. The primary focus of her invention is to utilize these combination therapies for the effective treatment of cancer, potentially improving patient outcomes.
Career Highlights
Throughout her career, Zelanna has made notable strides in the pharmaceutical industry, working with prestigious organizations like Merck Patent GmbH and Pfizer Corporation. Her experience at these leading companies has allowed her to refine her expertise in drug development and patenting innovative therapies.
Collaborations
Zelanna has collaborated with several talented individuals in her field, including her coworkers Glen Ian Andrews and Shihao Chen. These partnerships have enabled her to contribute to groundbreaking research and development, fostering an environment of innovation and creativity.
Conclusion
Zelanna Goldberg is a remarkable inventor whose work is paving the way for more effective cancer treatments through her patented PD-L1 antagonist combination therapies. Her contributions reflect her deep commitment to advancing medical science and improving the lives of patients battling cancer. As she continues to work alongside esteemed colleagues in prestigious organizations, her influence in the field is set to grow even further.